Pfizer considers selling animal-health and nutrition units

 Pfizer Incorporated has indicated that "it is exploring strategic options including sales and spin-offs for its animal-health and nutrition units, but will hold onto its generic-drug and consumer health-care businesses".

Part of the reasons behind the consideration of selling part of its business is to hone its focus on its core business of developing and marketing prescription drugs and vaccines. The animal-health and nutrition units together generated less than 10 percent of Pfizer's 2010 revenue of US$67.8 billion (€48.203 billion). Read more ...


This blog is written by Martin Little, The Global Miller, published and supported by the GFMT Magazine and the International Milling Directory from Perendale Publishers Ltd